3P Biopharmaceuticals continues its collaboration with U.S. biotech Zhittya for the treatment of Parkinson’s disease.

The process transfer and GMP supply of the FGF-1 candidate have been achieved successfully by both companies.

3P Biopharmaceuticals and the American biotech company, Zhittya Genesis Medicine (Zhittya), have successfully accomplished the process transfer and GMP supply of FGF-1 candidate.

3P and Zhittya began their relationship at the beginning of 2019 with 3P being selected as the CDMO to transfer the process for scaling up and performing cGMP manufacturing for clinical studies. After successfully achieving transfer of the process and its first cGMP batch in 2020, Zhittya requested manufacturing of the therapeutic candidate for a new mode of administration involving nasal treatment for use in its Clinical trial in Virgin Islands scheduled along 2023. According to preliminary studies conducted by Zhittya, the results for treating Parkinson’s disease using a nasal treatment are highly promising.
Zhittya has chosen human FGF-1 as its candidate protein. This particular growth factor is known for its ability to stimulate the growth of new blood vessels and neurons, making it an ideal therapeutic candidate for treating neurodegenerative diseases such as Parkinson’s disease.
Parkinson’s Disease affects a significant number of Americans, and recent research has shed light on a potential cause. The obstruction of blood flow to dopamine-producing neurons due to microvascular disorder has been linked to the development of the disease. However, there is hope for those suffering from this condition. Zhittya’s treatment, shows promise in slowing the progression of Parkinson’s Disease and potentially reversing its symptoms. This breakthrough offers hope to those affected and it underscores the importance of continued research and development in the field of neurology.
Dr. Jack Jacobs, President and Chief Science Officer at Zhittya, explains “We are very pleased with the collaboration with 3P regarding the tech transfer and GMP supply of our FGF-1 candidate. We hope that this partnership will extend to the manufacturing production of our drug candidates in the future and we look forward to bring us closer to developing effective treatments for those who need them the most.”
This partnership once again demonstrates the knowledge and capacity of 3P to carry out process development and manufacturing that is adapted to the needs of each client using microbial systems.

About Zhittya Regenerative Medicine Inc
Zhittya Regenerative Medicine (Zhittya means “life” in Ukrainian) is advancing a group of drugs which trigger the human body’s natural regeneration processes. Zhittya’s regenerative drugs act by specifically stimulating the growth of new blood vessels (a biological process termed “angiogenesis”) in tissues or organs that have perfusion defects. Lack of blood perfusion to an organ or tissue is the single biggest cause of death in the world. In fact, according to the Angiogenesis Foundation in Cambridge, MA, over 70 human diseases have been linked to a lack of blood perfusion. In addition to its work with Parkinson’s disease, Zhittya has clinical development programs in wound healing and cardiovascular medical conditions, all of which are characterized by a lack of blood perfusion. Further information: https://www.zgm.care

View the full press release here

Our dedicated team of specialists will be happy to discuss any of your CDMO supply chain needs. Contact us on +34 948 346 480 or email withinus@3pbio.com

Related Content

3P Biopharmaceuticals continues its successful collaboration with Toleranzia AB to fight Myasthenia Gravis.

Published: 19th September 2023
Toleranzia is at the forefront of innovation with their groundbreaking candidate, TOL2, designed to address the autoimmune neuromuscular disease, Myasthenia Gravis (MG).
Read more

3P Biopharmaceuticals lands in the United States.

Published: 8th June 2023
The Navarre biological CDMO inaugurates its first commercial office in Boston, supported by Keensight Capital.
Read more

The Regional Minister for Economic and Business Development Mikel Irujo meets with the management of 3P Biopharmaceuticals and its majority shareholder Keensight Capital.

Published: 23rd March 2023
During the meeting, attendees evaluated 3P's trajectory and its investment plan for the next five years.
Read more

Get in touch

Let’s discuss your biologics journey.

Discover more about our people, our passion, and how we can work together to improve lives.